Novartis’s main offerings for cardiovascular disease are drugs prescribed as a response to symptoms. However, heart problems can develop years before signs appear and the pharmaceutical giant wants to find new approaches to these disorders. A new partnership aims to develop artificial intelligence-based software that detects hidden cardiovascular conditions. The collaboration is with Anumana, company that develops algorithms that […]